{"doi":"10.1016/j.xkme.2020.01.012","title":"Acute Kidney Injury Following Encorafenib and Binimetinib for Metastatic Melanoma","abstract":"Nephrotoxicity is an important adverse effect of BRAF inhibitors, a class of drugs that are a mainstay for the treatment of advanced BRAFV600-mutant metastatic melanoma.1Launay-Vacher V. Zimner-Rapuch S. Poulalhon N. et al.Acute renal failure associated with the new BRAF inhibitor vemurafenib: a case series of 8 patients.Cancer. 2014; 120: 2158-2163Crossref PubMed Scopus (47) Google Scholar, 2Teuma C. Muzet M.P. Pelletier S. et al.New insights into renal toxicity of the B - RAF inhibitor, vemurafenib, in patients with metastatic melanoma.Cancer Chemother Pharmacol. 2016; 78: 419-426Crossref PubMed Scopus (27) Google Scholar, 3Wanchoo R. Jhaveri K.D. Deray G. Launay-Vacher V. Renal effects of BRAF inhibitors: a systematic review by the Cancer and the Kidney International Network.Clin Kidney J. 2016; 9: 245-251Crossref PubMed Scopus (47) Google Scholar Encorafenib, a new drug in this class, has recently been approved in combination with binimetinib, a MEK inhibitor, for patients with advanced metastatic melanoma.4Dummer R. Ascierto P.A. Gogas H.J. et al.Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS ): a multicentre , open-label , randomised , phase 3 trial.Lancet Oncol. 2018; 19: 1315-1327Abstract Full Text Full Text PDF PubMed Scopus (340) Google Scholar,5Dummer R. Ascierto P.A. Gogas H.J. et al.Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS ): a multicentre , open-label, randomised phase 3 trial.Lancet Oncol. 2018; 19: 603-615Abstract Full Text Full Text PDF PubMed Scopus (533) Google Scholar In the phase 1 trial of this combination, the maximum tolerated doses of encorafenib were 450 mg daily and 600 mg daily, but 450 mg became the US Food and Drug Administration–approved dose because 3 patients had unexplained acute kidney injury (AKI) at the higher dose.6Sullivan R.J. Weber J.S. Patel S.P. Dummer R. A phase Ib/II study of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus MEK inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma patients naive to BRAFi treatment.J Clin Oncol. 2015; 33: 9007Crossref Google Scholar Up to 93% of participants in the phase 3 COLUMBUS trial of the combination in patients with advanced melanoma experienced at least a 0.3-mg/dL increase in creatinine level.4Dummer R. Ascierto P.A. Gogas H.J. et al.Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS ): a multicentre , open-label , randomised , phase 3 trial.Lancet Oncol. 2018; 19: 1315-1327Abstract Full Text Full Text PDF PubMed Scopus (340) Google Scholar,5Dummer R. Ascierto P.A. Gogas H.J. et al.Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS ): a multicentre , open-label, randomised phase 3 trial.Lancet Oncol. 2018; 19: 603-615Abstract Full Text Full Text PDF PubMed Scopus (533) Google Scholar We aimed to describe the incidence, timing, and clinical features of AKI in patients receiving encorafenib-binimetinib for malignant melanoma. We retrospectively analyzed data from all patients who received encorafenib-binimetinib at Partners Healthcare between 2013 and 2019. Patients were identified using the Research Patient Data Registry by both medication list and natural language processing of electronic health records searching for “encorafenib,” “binimetinib,” or “enco-bini.” Using chart review, we recorded baseline demographics, comorbid conditions, medications, laboratory studies, and encorafenib-binimetinib dose and start date. Patients were followed up for 1 year. The Kidney Disease: Improving Global Outcomes (KDIGO) criteria were used to diagnose and grade AKI.7Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work GroupKDIGO clinical practice guideline for acute kidney injury.Kidney Int Suppl. 2012; 2Google Scholar The caus","journal":"Kidney Medicine","year":2020,"id":88956,"datarank":0.3453877639491069,"base_score":2.302585092994046,"endowment":2.302585092994046,"self_citation_contribution":0.3453877639491069,"citation_network_contribution":0.0,"self_endowment_contribution":0.3453877639491069,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":9,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9595,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":451967,"name":"Halla Bates","orcid":null,"position":1,"is_corresponding":false},{"id":322187,"name":"Donald F. Chute","orcid":null,"position":2,"is_corresponding":false},{"id":268728,"name":"Ian A. Strohbehn","orcid":"0000-0003-2167-2896","position":3,"is_corresponding":false},{"id":450746,"name":"Samuel Strohbehn","orcid":"0009-0002-5627-0774","position":4,"is_corresponding":false},{"id":365632,"name":"Riley Fadden","orcid":null,"position":5,"is_corresponding":false},{"id":105169,"name":"Kerry L. Reynolds","orcid":"0000-0002-7793-654X","position":6,"is_corresponding":false},{"id":232176,"name":"Justine V. Cohen","orcid":"0000-0003-4803-9230","position":7,"is_corresponding":false},{"id":412,"name":"Ryan J. Sullivan","orcid":"0000-0001-5344-6645","position":8,"is_corresponding":false},{"id":263649,"name":"Meghan E. Sise","orcid":"0000-0002-4327-9713","position":9,"is_corresponding":false},{"id":268727,"name":"Harish Seethapathy","orcid":"0000-0002-1171-1022","position":0,"is_corresponding":true}],"reference_count":7,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-18T22:01:50.225871Z","pmid":"32734258","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}